CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., is heading distribution in the United States.
If you are not happy with the results below please do another search
50 search results for:
Initial results from Jazz Pharmaceuticals’ Phase III study on Sativex (JZP378) for the treatment of multiple sclerosis failed to achieve the primary endpoint of an improvement in muscle tone.
The World Health Organization says “sustained transmission” of monkeypox worldwide could see the virus begin to move into high-risk groups, such as pregnant women, immunocompromised people and children.
Germany’s BioNTech, Pfizer’s partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.
French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for a 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.
The FDA’s Vaccines and Related Biological Products Advisory Committee voted 19-2 that the next wave of COVID booster shots should include a component that targets the Omicron variant of the coronavirus.
The European Commission proposed on Wednesday to ban the sale in the EU of flavored heated tobacco products after a big rise in their consumption.
As per the modified supply agreement with the government, Lilly will provide an additional 150,000 doses of bebtelovimab for about $275 million. The drug has also shown effectiveness against the Omicron variant.
The U.S. government is ramping up efforts to staunch the spread of monkeypox by sending hundreds of thousands of vaccine doses to states in the coming months, expanding access for those most at risk and increasing supply to areas with high case numbers.
Pfizer and Roivant Sciences unveiled a new company called Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.